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Abstract  
The challenge of eliminating Pseudomonas aeruginosa infections, such as in cystic fibrosis lungs, 
remains unchanged due to the rapid development of antibiotic resistance. Poor drug penetration 
into dense P. aeruginosa biofilms plays a vital role in ineffective clearance of the infection. Thus, the 
current antibiotic therapy against P. aeruginosa biofilms need to be revisited and alternative anti-
biofilm strategies need to be invented. Fungal quorum sensing molecule (QSM), farnesol, appear to 
have detrimental effects on P. aeruginosa. Thus, this study aimed to co-deliver naturally occurring 
QSM farnesol, with the antibiotic ciprofloxacin as a liposomal formulation to eradicate P. aeruginosa 
biofilms. Four different liposomes (with ciprofloxacin and farnesol: Lcip+far, with ciprofloxacin: Lcip, 
with farnesol: Lfar, control: Lcon) were prepared using dehydration-rehydration method and 
characterized. Drug entrapment and release were evaluated by spectrometry and high performance 
liquid chromatography (HPLC). The efficacy of liposomes was assessed using standard biofilm 
assay.  Liposome-treated 24h P. aeruginosa biofilms were quantitatively assessed by XTT reduction 
assay and crystal violet assay, qualitatively by confocal laser scanning microscopy (CLSM) and 
transmission electron microscopy (TEM). Ciprofloxacin release from liposomes was higher when 
encapsulated with farnesol (Lcip+far ) compared to Lcip (3.06% vs 1.48%) whereas  farnesol release 
was lower when encapsulated with ciprofloxacin (Lcip+far ) compared to Lfar (1.81% vs 4.75%). The 
biofilm metabolism was significantly lower when treated with Lcip+far or Lcip compared to free 
ciprofloxacin (XTT, P<0.05). When administered as Lcip+far, the ciprofloxacin concentration required 
to achieve similar biofilm inhibition was 125-fold or 10-fold lower compared to free ciprofloxacin 
or Lcip respectively (P<0.05). CLSM and TEM confirmed predominant biofilm disruption, greater 
dead cell ratio and increased depth of biofilm killing when treated with Lcip+far compared to other 
liposomal preparations. Thus, co-delivery of farnesol and ciprofloxacin is likely to be a promising 
approach to battle antibiotic resistant P. aeruginosa biofilms by enhancing biofilm killing at 
significantly lower antibiotic doses. 
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Introduction 
The opportunistic bacterial pathogen, Pseudomonas aeruginosa is one of the leading causes of 
nosocomial infections worldwide and ranked the second most prevalent among the Gram-negative 
pathogens reported to the National Nosocomial Infection Surveillance System 1. In the USA, 
approximately 51,000 healthcare-associated P. aeruginosa infections occur annually and 
alarmingly, over 6,000 (13%) of these infections are caused by multidrug-resistant variant of the 
pathogen 2. P. aeruginosa is the most commonly isolated pathogen in lung infections in cystic 
fibrosis patients and is considered as the leading cause for morbidity and mortality in such 
patients3. Despite aggressive therapeutic approach, current antibiotic treatments could only 
accomplish an adjournment of the spread of the pathogen as well as the destruction of the lung 
tissues; mucus-embedded biofilms persist for decades and cannot be completely eradicated.  Thus, 
the applications of current armory of antimicrobial compounds against P. aeruginosa biofilm 
infections are needed to be revisited and alternative anti-biofilm drugs and strategies are ought to 
be sought 4. 
P. aeruginosa biofilms are multicellular surface-attached and spatially oriented, bacterial 
communities encased in an extracellular matrix that display characteristic and significant 
resistance to antimicrobial agents and environmental stresses.  Limited drug penetration through 
the biofilm matrix 5, nutrients and oxygen-based heterogeneity of the bacterial cell populations 6, 
biofilm specific bacterial phenotypes6, subpopulations of multidrug resistant persister cells 7, and 
bacterial communications via quorum sensing and signal transduction systems 8 are suggested to 
contribute the drug resistance associated with P. aeruginosa biofilms. As a result of significant 
antibiotic tolerance, individual antibiotic therapy often fails to eliminate P. aeruginosa infections in 
CF patients and combined antibiotic therapies at high concentrations are required in managing 
acute CF related infections 9.  
A variety of antibiotic treatment strategies such as systemic and nebulized antibiotics have been 
employed to treat P. aeruginosa biofilms in CF lungs 10-12. However, to date, no therapeutic approach 
has achieved complete eradication of P. aeruginosa from the chronic lung infections most likely due 
to biofilm-specific intrinsic antibiotic resistance. In particular, the efficacy of aminoglycosides, 
widely used first-line therapy in the management of CF infections, is limited due to their chemical 
interactions with the biofilm matrix resulting slow and incomplete drug penetration into the 
bacterial biofilm core 13. Conversely, Low pH in the biofilm matrix facilitates antibacterial agents 
such as ciprofloxacin to strongly bind to the alginates within the biofilm causing significant 
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reduction in the effective drug concentrations at the target site. Alarmingly, antibiotic doses below 
Minimum Inhibitory Concentrations (MIC) i.e. sub-MICs of tobramycin have recently been found to 
promote P. aeruginosa biofilm formation, and to generate drug resistant bacterial strains 14, 15.  
Encapsulation of the drugs in to liposomes was recently introduced in overcoming nonspecific 
drug-binding to extracellular matrix and the metabolic protection in the biofilm and appears greatly 
to aid in delivering the drug of interest to the target site.  For instance, liposomal amikacin 
demonstrated a high drug loading, long term stability, slow and sustained drug release, and a 
greater potential for in vitro penetration through mucus to reach the biofilm cells of P. aeruginosa 
16. Furthermore, drug delivery via liposomes potentially aids persister cell eradication due to slow 
and sustained release of the drug providing long term localized high concentrations of the antibiotic 
compared to free form of the drug in order to kill persister cells 17, 18. .  
In recent studies, a 12-carbon sesquiterpene; farnesol,  a known virulence factor and repressor of 
yeast to hyphae morphological transition in Candida albicans 19-25 , was shown to inhibit the 
synthesis of P. aeruginosa  quorum sensing molecule (QSM), 2-heptyl-3-hydroxy-4-quinolone 
(Pseudomonas quinolone signal: PQS), PQS-regulated virulence factor pyocyanin 26,  and bacterial 
swarming motility 27. Importantly, PQS is shown to play an important role in the biofilm formation 
of P. aeruginosa 28. Hence, we speculate that farnesol possesses inhibitory effects on P. aeruginosa 
biofilm development.  
Quorum sensing has not been targeted before in the management of CF lung infections, and co-
delivery of antibiotics and QSMs has never been attempted. Thus, the aim of this study was to co-
deliver a naturally occurring fungal QSM (farnesol), and a well-established antipseudomonal 
antibiotic (ciprofloxacin), in the form of liposomes to P. aeruginosa biofilms. We hypothesized that a 
liposomal delivery system of farnesol with ciprofloxacin will efficiently disrupt and eliminate P. 
aeruginosa biofilms by targeting multiple mechanisms of biofilm development and maintenance 
compared to antibiotic treatment alone. 
 
Material and methods 
Preparation of liposomes 
For each experiment, 4 different formulations of liposomes were freshly prepared. These included: 
liposome only (Lcon), Liposome with ciprofloxacin (Lcip), liposomes with farnesol (Lfar) and liposome 
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with ciprofloxacin and farnesol (Lcip+far). Liposomes were prepared as described by Lagace et al with 
modifications 29. DPPC (1,2-Dipalmitoyl-sn-glycero-3-phosphocholine, Genzyme Pharmaceuticals, 
Switzerland) and cholesterol were added 4:1 molar ratio and dissolved in chloroform (HPLC grade, 
Fisher Scientific, USA) in a 1:1 w/v ratio. Farnesol 2μl (0.879g/ml density) was added to the 
dissolved lipid solution and mixed thoroughly for Lfar and Lcip+far preparations. The lipid solutions 
were evaporated to form a thin layer of lipid using a rotary evaporator (Buchi R-210 rotovapor, 
Buchi Labortechnik, Switzerland). The flasks were stored under a vacuum for an hour to remove 
any residual chloroform. 
Ten milliliters of unbuffered saline (for Lcon and Lfar) or 10ml of 3mg/ml ciprofloxacin dissolved in 
unbuffered saline (for Lcip and Lcip+far , Ciprofloxacin hydrochloride USP grade, Letco Medical, 
Decatur, USA, Catalog No. 690953) were added to the flasks and sonicated in a water bath for 5 min. 
The formed multi lamellar liposomes were collected, centrifuged at 15000rpm for 10min at 40C. 
The supernatant was collected and the pellet was resuspended in unbuffered saline, washed and 
washes were collected. The resulting liposome pellet was resuspended in unbuffered saline as 
necessary and used for liposome characterization and microbiological studies.  
Determination of drug entrapment efficiency 
Ciprofloxacin entrapment  
To determine the entrapped ciprofloxacin, the optical density of the supernatant and washes 
collected during the preparation of liposomes was read in a spectrophotometer (Infinite M200, 
Tecan Systems Inc., CA, USA) at 272nm. The entrapment efficiency (EE) was calculated using 
following formula; 
Total	quantity	of	ciprofloxacin	added − the	quantity	of	unbound	ciprofloxacin×100 
Total	quantity	of	ciprofloxacin	added 
 
Farnesol entrapment  
The entrapment of farnesol was quantified using High Performance Liquid Chromatography (HPLC) 
as described by Chen et al 2009 30. Supernatant and wash were filtered through 0.22μm sterile 
filters before performing HPLC.  The assay was performed on a Waters 2495 HPLC system with a 
C18 reverse phase column (μBondapak®, 3.9×300mrn column, Waters Corporation, MA, USA).  The 
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following conditions were used in the HPLC assay: mobile phase Acetonitrile: water (80:20 V/V); 
the flow rate 1ml/min; UV detection at 210nm; retention time 6min. All samples were analyzed in 
duplicates.  
Farnesol entrapment was calculated as follows; 
Total	quantity	of	farnesol	added − the	quantity	of	unbound	farnesol	×100 
Total	quantity	of	farnesol	added 
 
Characterization of liposomes 
Particle size and zeta potential 
The size, polydispersity index and the zeta potential of liposomes were determined by Dynamic 
Light Scattering Zetasizer Nano ZS (Malvern instruments Ltd, UK).  
Morphology of liposomes 
The morphology of liposomes was visualized by transmission light microscope (TLM, Leica TCS 
SP5, Leica Microsystems, IL) fluorescent microscopy (FM, Stained with propidium iodide, Leica TCS 
SP5, Leica Microsystems, IL) and Scanning electron microscopy (SEM). In order to prepare 
liposomes for the latter, liposomes were placed on a coverslip and coated with Platinum/Palladium 
(Cressington sputter coater 208 HR, Cressington Scientific Instruments Ltd, UK). The surface 
topography of liposomes was visualized with scanning electron microscope (Zeiss Supra 40VP, CA, 
USA) in high-vacuum mode. 
Drug release  
Ciprofloxacin release from the liposomes were studied as described by Halwani M. et al 2008 with 
modifications 31. The modified assay used in this study is similar to agar diffusion assay. However, 
UV absorbance at 272 nm was used to estimate ciprofloxacin concentration instead of the zone of 
inhibition of microbial growth due to the potential variations of antibiotic penetration efficiencies 
through agar, asymmetry of zone of inhibition and variations among the microorganism used in 
agar diffusion. 
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Known volumes of liposomes were added to 10ml of saline and incubated at 370C for 24h in a 
shaker (250rpm). The liposomal suspensions were withdrawn in defined time intervals, 
centrifuged (15000rpm, 10 min) and the absorbance of the supernatant was measured at 272nm 
(Infinite M200, Tecan Systems Inc., CA, USA) to estimate ciprofloxacin release . The liposome pellet 
was re-suspended in fresh saline (10ml) after each time interval to prevent possible antibiotic 
saturation. 
After 24h of incubation, a sample was prepared as mentioned above and filtered (0.22μm). The 
quantification of farnesol released was assessed by HPLC assay as described above.  
Microorganisms and growth conditions 
Pseudomonas aeruginosa PAO1 was used throughout the study. The identity of the bacteria was 
confirmed with the commercially available API 20 E kit (Biomérieux, Mercy I’Etoile, France). All 
isolates were stored in multiple aliquots at -200C, after confirming their purity. Blood Agar (Sigma 
Aldrich, USA) and Brain Heart Infusion (BHI, Sigma Aldrich, USA) solutions were used for culturing 
P. aeruginosa. 
Prior to each experiment, P. aeruginosa was subcultured on blood agar for 18 h at 370C. A loopful of 
the overnight bacterial growth was inoculated into BHI medium, and, incubated for 18h in an 
orbital shaker (80 rpm) at 370C. The resultant growth was harvested, washed twice in Phosphate 
Buffered Saline (PBS, pH 7.2) and resuspended. The concentration of P. aeruginosa was adjusted 
1×107 cells/ml by spectrophotometry and confirmed by hemocytometric counting.  
Biofilm Formation 
P. aeruginosa biofilms were developed as described by Bandara et al 32 with some modifications. 
Commercially available pre-sterilized, polystyrene, flat bottom 96-well microtiter plates (BD 
Biosciences, California, USA) were used. Hundred µl of a standard cell suspension of bacteria 
(107organisms/ml) was prepared and transferred into the wells of a microtiter plate, and the plate 
was incubated for 1.5h (370C, 80 rpm) to promote microbial adherence to surface of the wells. After 
the initial adhesion phase, the cell suspensions were aspirated and each well was washed twice 
with PBS to remove loosely adherent cells. A total of 200µl of BHI was transferred to each well and 
the plate was incubated for 24 h (370C, 80 rpm), and wells washed twice with PBS to eliminate 
traces of the medium. The resultant biofilms were considered ready for experimental use. 
Determination of minimum inhibitory concentration (MIC) 
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Planktonic phase 
MIC was determined by a broth microdilution assay in accordance with the CLSI guidelines 33. 
Briefly, bacterial cell suspensions (5×105 Cells/ml) were treated with ciprofloxacin or farnesol in a 
concentration gradient (two-fold) and incubated in a 96 well microtiter plate for 24h at 350C. At the 
end of the incubation, the optical density was measured by a spectrophotometer at 595 nm. The 
lowest concentration of the antibiotic or farnesol at which the bacteria demonstrated visible 
growth inhibition compared to the solvent control was considered the MIC of the antibiotic or 
farnesol against P. aeruginosa. The assay was performed in quadruplicates at three times. 
Biofilm phase 
P. aeruginosa biofilms were grown in sterile 96 well plates (BD Biosciences, USA) as described 
above. Biofilms were washed twice with PBS and ciprofloxacin or farnesol was administered in a 
concentration gradient (two fold). The plates were incubated for 24h at 370C and 80 rpm.  
At the end of the incubation period, a XTT (sodium 2,3,-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-
[(phenylamino)-carbonyl]-2H-tetrazolium inner salt) reduction assay was performed to quantify 
the viability of biofilms as described in following sections. The lowest concentration of the 
antibiotic or farnesol at which the bacteria demonstrate 80% of reduction of the viability compared 
to the solvent control is considered as the Minimum Biofilm Inhibitory Concentration (MBIC) of the 
antibiotic or farnesol against P. aeruginosa. The assay was performed quadruplicates three separate 
times. 
In addition, as described in following sections, a crystal violet assay was performed at the end of the 
incubation to estimate the effect of farnesol on the biomass of the mature P. aeruginosa biofilms. 
The assay was performed in quadruplicates at three separate times. 
Treatment of biofilms with liposomes  
P. aeruginosa biofilms were developed in 96 well plates as described above. Freshly prepared 
liposomes (Lcon, Lcip, Lfar and Lcip+far) were added in a concentration gradient to the biofilms with BHI 
and incubated for another 24h (370C, 80rpm). At the end of this incubation, biofilms were washed 
twice with PBS and a XTT reduction assay was performed. Each experiment was conducted in 
quadruplicates on three different occasions. 
XTT reduction assay 
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At the end of incubation of both test and control biofilms, a standard XTT (sodium 2,3,-bis(2-
methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)-carbonyl]-2H-tetrazolium inner salt) reduction 
assay was performed as described by Bandara et al 34 to measure the viability of biofilms by means 
of bacterial cell metabolic activity. In brief, commercially available XTT powder (Sigma, MO, USA) 
was dissolved in PBS to a final concentration of 1 mg/ml. Then the solution was filter-sterilized 
(0.22 μm pore size filter) and stored at -700C. Freshly prepared 0.4 mM menadione solution was 
used for XTT reduction assay. Thawed XTT solution was mixed with menadione solution in a 20:1 
(v/v) ratio immediately before the assay. Thereafter, PBS: XTT: Menadione in a 79:20:1 ratio were 
added into each well containing biofilms and incubated in the dark for 5 h at 370C. The color 
changes were measured with a microtiter plate reader (Infinite M200 microplate reader, TECAN US 
Inc, NC, USA) at 492nm.  
Crystal violet assay 
At the end of incubation of both test and control biofilms, a crystal violet assay was performed to 
quantify biofilm biomass. Biofilms were carefully washed twice with PBS and stained with a 1% 
crystal violet solution for 15 min at 250C without shaking. Wells were carefully washed three times 
with PBS to remove excess stain and air dried at room temperature. Thirty percent acetic acid was 
added to the wells containing stained biofilms and incubated for 20 min at 250C. The solution was 
transferred to a new well plate and the optical density was measured at 570nm.  
Confocal Laser Scanning Microscopy (CLSM) 
Biofilms were prepared on cover slips placed in flat bottom six well plates (Nunclon, Nunc, thermo 
Fisher scientific, USA) as described above. Pre-formed 24h biofilms were exposed to all 4 different 
liposomal preparations and incubated for another 24h at 370C in a shaker (80rpm). At the end of 
incubation, the prewashed films were stained with Live and Dead stain (Live/Dead BacLight 
Bacterial Viability kit, Invitrogen, Eugene, USA) 32. The biofilm was then analyzed using confocal 
laser scanning microscopy 
Transmission electron microscopy (TEM) 
P. aeruginosa biofilms were prepared on ACLAR® film (Electron Microscopy Sciences, PA, USA) and 
treated with various liposomal preparations as described above. At the end of the incubation, 
biofilms were washed twice with PBS and fixed with an aldehyde mixture for 2-4h on ice (4% 
gluteraldehyde, 2% paraformaldehyde, 0.1M cacodylate, 2mM Ca and 4mM Mg). The samples were 
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then washed three times with 0.1M sodium cacodylate buffer (pH7.4, Electron Microscopy Sciences, 
PA, USA) for 15 min. Subsequently, the biofilms were fixed with reduced osmium (1:1 4% 
potassium ferrocyanide in 0.2M cacodylate buffer: 4% osmium tetroxide) in a microwave (100w, 3 
sessions of 2 min on, 2 min off, two times). After fixation, the samples were washed 5 times with 
water for 10 min and dehydrated with ethanol (15 min each, 50%, 70%, and 95%, and 2×100% 
ethanol) and 100% acetone (15 min, two times). The samples were placed in a polymerization tray 
and infiltrated with resin (30%, 66% and 2×100% resin in 100% acetone) and polymerized for 2 
days at 600C. The samples were then sectioned using a Leica UltraCut Ultramicrotome® (Leica 
Microsystems Inc. IL, USA), placed on grids and observed under an FEI Tecnai Transmission 
Electron Microscope® (FEI, Oregon, USA) at 80kV. 
Statistical analysis 
Statistical analysis was performed using SPSS software (version 16.0). Mann—Whitney U-test was 
performed to compare the significant differences between corresponding controls and test samples 
of the P. aeruginosa biofilms. A P-value of less than 0.05 was considered statistically significant. 
Results 
Characteristics of liposomes 
The entrapment efficiencies of ciprofloxacin were 60% in Lcip+far and 61% in Lcip. Farnesol 
entrapment efficiencies were 91% in Lcip+far and 93% in Lfar. The diameters of Lcon, Lcip, Lfar and Lcip+far 
were 2808.0±529.6nm, 677.8±46.6nm, 684.0±43.8nm and 536.8±21nm respectively. Lcon were 
significantly larger than all three test liposomes and the difference in the diameters of test 
liposomes were insignificant (P<0.05). The zeta potentials of respective liposomes were -1.66mV, -
3.27mV, +0.09mV and -0.11mV (Table 1) and polydispersity indices of respective liposomes were 
0.086, 0.281, 0.391 and 0.213. 
Morphology of liposomes 
FM, TLM and SEM confirmed that the liposomes were spherical in shape and varied somewhat in 
size but were consistent with DLS measurements (control liposomes; Lcon, Figure 1). FM images 
exhibited a fluorescently stained liposomal membrane and an unstained dark core (Figure 1).  
Drug release 
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After 24h of drug release, 3.06% (18.04μg) of total encapsulated ciprofloxacin (589.14μg) was 
released from Lcip+far, however, only 1.48% (13.27μg) of the total encapsulated ciprofloxacin 
(897.09μg) was released from Lcip.  During a period of 24h, there was a continuous and a greater 
release of ciprofloxacin from Lcip+far compared to Lcip (Figure 2). 
After 24h, 1.81% (13.08μg) of total farnesol encapsulated (723.14μg) was released from Lcip+far. In 
contrast, 4.75% (35.13μg) of total farnesol encapsulated (738.91μg) was released from Lfar. 
Minimum inhibitory concentrations (MIC) 
The MIC of ciprofloxacin was 0.125μg/ml for planktonic P. aeruginosa and MBIC was 16μg/ml for 
24h developed P. aeruginosa biofilms.   
Farnesol did not have any significant effects on the P. aeruginosa planktonic phase, even up to 
175μg/ml. In contrast, the maximum reduction of metabolic activity as indicated by XTT readings 
(40% reduction compared to solvent controls, P<0.05) were observed at farnesol concentrations of 
90μg/ml in established P. aeruginosa biofilms. 
A crystal violet assay showed that concentrations of farnesol equal to or greater than 2.8μg/ml 
resulted in the greatest reduction in the biofilm biomass (45%, P<0.05) compared to its controls. 
Effect of liposomes on the metabolism of established P. aeruginosa biofilms- XTT reduction 
assay  
At the end of the 24h treatment of P. aeruginosa biofilms with various liposomal formulations, 
significant treatment effects were observed.  The biofilms treated with Lcip+far showed a significantly 
lower metabolic activity compared to Lcip and free ciprofloxacin.  Only ≥0.128μg/ml (P<0.05) of 
ciprofloxacin concentrations delivered from Lcip+far resulted in bacterial metabolic activity (80% 
reduction compared to control) equal to those observed in Lcip treated biofilms at ≥1.310μg 
(P<0.05) and, in contrast, 16μg/ml of free ciprofloxacin treated biofilms (P<0.05, Figure 3). 
Treatment with Lfar and Lcon did not exhibit any reduction of the P. aeruginosa biofilm metabolism 
compared to controls, as manifested by the XTT readings. 
Effect of liposomes on P. aeruginosa biofilms - Confocal laser scanning microscopy 
CLSM imaging also demonstrated the significant effect of the drug loaded liposomal preparations on 
P. aeruginosa pre-formed biofilms. Biofilms treated with liposomes containing either ciprofloxacin 
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(Lcip), farnesol (Lfar), or both (Lcip+far, Figure 4D, E, and F) exhibited a greater degree of structural 
disruption and a lower live: dead cell ratio compared to the dense, well-organized, undisturbed 
biofilm (Figure 4A) and biofilms treated with control liposomes (Lcon, Figure 4C). It was clearly 
visible that the biofilms treated with Lcip+far revealed the most significant disruption, exhibiting 
lessened biofilm mass/architecture and a significant proportion of dead cells compared to all other 
treatment combinations tested (Figure 4F). Interestingly, the biofilms treated with free 
ciprofloxacin demonstrated only isolated areas of cell death and were relatively undisrupted and 
appeared to be viable (Figure 4B) compared to Lcip and Lcip+far treated biofilms (Figure 4E and F).  
Figure 5 shows the longitudinal and horizontal sections of P. aeruginosa biofilms treated with 
various liposomal formulations. The biofilms treated with liposomal control, Lcon, showed preserved 
dense biofilm architecture and the viability deeper bacterial cell layers.  The dead and dying cells 
appeared only in the superficial cell layers of the biofilm (Figure 5A). Similarly, the Lfar treated 
biofilm also exhibited a spatially oriented biofilm structure; however, regions of bacterial death 
were also noted (Figure 5B). The thickness of the dead cell layers in the Lfar treated biofilm was 
greater than that of Lcon treated biofilm and in some areas,the full thickness of the biofilm consisted 
of dead cells (Figure 5B). Compared to the Lcon and Lfar treated biofilms, the Lcip treated biofilms 
exhibited a greater disruption of the biofilm architecture and higher proportions of dead cells 
(Figure 5C). However, live cells were still existed in the deeper layers of the biofilm (Figure 5C). In 
contrast, the Lcip+far treated biofilm showed the most significant quantities of dead bacteria 
compared to any of the other liposome treated biofilms. More importantly, the full thickness of the 
majority of the areas of the biofilm was filled with dead cells and the entire biofilm appeared dead 
(figure 5D). 
Effect of liposomes on P. aeruginosa biofilms – Transmission electron microscopy 
TEM imaging corroborated with the CSLM findings of the biofilms treated with various liposomal 
preparations. P. aeruginosa cells in the control, untreated biofilms appeared to be healthy with a 
rod shaped cell structure and dark intracellular materials. Cells were loosely packed and some 
clearly showed intact cell membranes and slimy secretions in their immediate environment. There 
were few dead cells (observed as clear cells), while some cells showed disintegration of cell 
membrane and cellular detritus (Figure 6A). Similarly, Lcon treated biofilms also showed healthy 
heterogeneous bacteria with some dividing cells. Cell membranes were intact and no dead cells 
were visible (Figure 6B). Similar to the Lcon treated biofilm, Lfar treated biofilm also consisted of 
healthy bacteria with some pale colored/less condensed intracellular materials (Figure 6C). In 
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contrast, Lcip treated biofilms had higher numbers of dead cells/clear cells. The cell membranes of 
the majority of the cells were disintegrated and the cellular contents appear to be leaked out. Small 
vesicles were also present surrounding dead cells (Figure 6D). Most importantly, the Lcip+far treated 
biofilms also exhibited the highest proportion of clear and partially ruptured cells. Some 
disintegrated cells contained cytoplasm filled vesicles. Cell debris of dead cells was distributed 
throughout the microscopic field (Figure 6E).  
Discussion 
The biofilm antibiotic resistance and the synthesis of various virulence determinants During P. 
aeruginosa biofilm formation are mediated by two major and chemically distinct quorum sensing 
systems; N-acetyl homoserine lactones and the 4-quinolones. Among all quinolones, only PQS (2-
heptyl-3-hydroxy-4-quinolone, Pseudomonas Quinolone Signal, PQS) is isolated in broncho-alveolar 
lavage fluid in CF lungs suggesting the potential association of PQS with P. aeruginosa infections and 
subsequent inflammatory damage to host respiratory tissues in CF patients 26, 35, 36.  
The role of PQS in P. aeruginosa biofilm development is well-known. PQS enhances P. aeruginosa 
biofilm formation by stimulating two known regulators of biofilm development; RhlR/C4-HSL and 
RpoS 37. Also, PQS regulates the synthesis of extracellular DNA (eDNA) in P. aeruginosa biofilms. 
eDNA acts  as a cell-cell interconnecting compound that predominantly maintain the 3D structure 
and architecture of P. aeruginosa biofilms 38. eDNA is also isolated at very high concentrations in 
sputum samples of CF lungs (up to 20mg/ml), suggesting the existence of eDNA rich micro colonies 
of P. aeruginosa in CF lungs 39. Alarmingly, eDNA enriched P. aeruginosa biofilms showed up to 640-
fold more antibiotic resistance than planktonic cultures 40. Importantly, PQS regulates the synthesis 
of various other extracellular proteases such as hydrogen cyanide and redox active phenazines like 
pyocyanin in P. aeruginosa26, 41. Pyocyanin, in turn, generates the reactive oxygen species (ROS) 
superoxide and hydrogen peroxide 42. These ROS favor bacterial colonization by damaging various 
host cells by neutrophil apoptosis, induction of IL-8 and inhibition of the dual-oxidase based 
antimicrobial system in airway epithelia 43, 44. Thus, pyocyanin producing P. aeruginosa strains are 
more difficult to clear from the lung by host immune reactions than non-pyocyanin producing P. 
aeruginosa strains 45. In addition, PQS induces P. aeruginosa to enter into a metabolically less active 
state to cope external stresses such as antibiotics 46. Due to its prominent role in P. aeruginosa 
biofilm development and maintenance, PQS appears as an attractive target for novel therapeutic 
strategies in pathogenic biofilm elimination by improving drug delivery.  
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A major QSM secreted by Candida albicans, E,E-farnesol, has been identified to significantly reduce 
PQS synthesis in P. aeruginosa 26. In addition, farnesol is known to inhibit swarming of P. 
aeruginosa, most likely through inhibiting PQS synthesis 27. Interestingly, using The Lubbock 
Chronic Wound Biofilm model, recent research revealed that farnesol at a concentration of 
1,000μg/ml could completely suppress the development of P. aeruginosa biofilms  47. Moreover, a 
role of farnesol in potentiating bacterial susceptibility to antibiotics has been recently unveiled 48. 
Hence, we designed a novel drug delivery system, exploiting aforementioned anti-pseudomonas 
properties of farnesol, using well-established liposomes to co-deliver ciprofloxacin and farnesol 
simultaneously. The latter delivery system was expected to achieve superior elimination of mature 
P. aeruginosa biofilms through farnesol-mediated inhibition of PQS synthesis and ciprofloxacin-
mediated killing of the bacteria. Furthermore, farnesol has very low aqueous solubility and is 
lipophilic, attributes making formulation in liposomes an attractive option.  
Liposomes were originally developed for use in intravenous drug delivery systems. For localized 
target release of the antibiotic such as in managing lung infections, liposomes must be intact until 
reaching the desired site of infection and have slow and sustained drug release. The therapeutic use 
of liposomes for inhaled drug delivery has been recently studied 49-51. Liposomes are expected to 
deliver antibiotics sufficiently and sustainably to the site of infection in the lung. In effect, when 
tobramycin is administered intratracheally in the form of liposomes, drug retention and 
antimicrobial activity in the lung are significantly enhanced 52-54. To synthesize liposomes with 
substantial encapsulation of both ciprofloxacin and farnesol that exhibit a slow and sustained 
release, we experimented with various combinations of DPPC and cholesterol. The optimal ratio of 
these lipids for drug encapsulation and release was 4:1 DPPC: Cholesterol (data not shown). The 
resultant, drug-loaded multi lamellar liposome populations were heterogeneous as indicated by the 
polydispersity indices and ranged between 500-700nm in diameter.  Zeta potential is a valuable 
physicochemical parameter that determines the stability of any nanosuspensions such as 
liposomes.  The repulsion between liposomes with similar electric charges ensures easy 
redispersion of the particles and prevents their aggregation. Hence, extremely positive or negative 
zeta potential values are preferred55, 56, i.e. a minimum zeta potential of ± 20 mV is desirable for 
combined  electrostatic  and steric stabilization of a nanosuspension 57 . However, all the multi 
lamellar liposomes prepared in our study demonstrated weak zeta potentials (between 0±5mV) 
and the tendency toward liposomal aggregation was confirmed through TLM imaging, where some 
liposomal aggregates were visible among individually dispersed liposomes. Thus, weak charge of 
liposomes may have influenced its stability, drug encapsulation and their adsorption to pathogens 
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58.  Addition of surfactant may have added an advantage of dissolution of farnesol and increase the 
stability of liposomes. However, due to potential cytotoxic effects of various surfactants on P. 
aeruginosa biofilms  and to simplify the liposomal composition, surfactants were not used 59. 
Nevertheless, the liposomes reported here will be further optimized for a desirable zeta potential 
and stability in the future.   
The relevance of the liposomal charge and its capability of penetration to the biofilms have been 
recently studied 60. John et al showed that the penetration of oral and topical bacterial biofilms by 
charged (+ or -) liposomes was significantly higher than that of free drug 61-63. In contrast, 
uncharged liposomes demonstrated more favorable interactions with planktonic P. aeruginosa 64. In 
concurrence with these findings, our liposomes were weakly charged (+ or -) and thus expected to 
penetrate P. aeruginosa biofilms more effectively than free drug. The CLSM images presented in this 
study further supported the enhanced penetration of liposome into P. aeruginosa biofilms. 
Compared to free ciprofloxacin treated biofilms, Lcip and Lcip+far exhibited significantly higher ratio of 
biofilm death, likely due to enhanced penetration. In particular, Lcip+far treated biofilms showed 
bacterial cell death throughout the full thickness of the biofilms compared to other tested liposomal 
formulation exhibiting its properties of superior biofilm killing. TEM images were also consistent 
with these observations and Lcip and Lcip+far killed more bacteria in P. aeruginosa biofilms compared 
to other liposomal preparations. 
In the design of liposomes, farnesol was expected to be entrapped in the lipid bilayer due to its lipid 
solubility, whereas the water soluble ciprofloxacin was expected to be encapsulated in the core of 
the liposome. Farnesol demonstrated a very high efficiency of entrapment in both Lfar and Lcip+far, 
(over a 90% entrapment). However, the release of farnesol from Lcip+far was 40% lower than that 
from Lfar during a 24h period, suggesting that the presence of ciprofloxacin affects the release of 
farnesol. Drug release from liposomes is known to be influenced by the membrane composition and 
the biochemical properties of the encapsulated drug (charge, pKas, drug stability, pH, etc.). Though 
the exact reason is yet to be unraveled, the presence of ciprofloxacin may have altered the 
liposomal stability resulting reduced farnesol release65-67.  Similar to farnesol entrapment, 
ciprofloxacin was also entrapped in liposomes efficiently regardless of the presence of farnesol. 
However, ciprofloxacin showed constantly higher rates of release from Lcip+far compared to Lcip 
throughout a 24h period, indicating that the presence of farnesol in the liposome increased the 
release of the antibiotic by two fold. Hence, from a drug release point of view, Lcip+far was a preferred 
Page 15 of 33
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
antibiotic release system despite possessing similar entrapment efficiencies of farnesol and 
ciprofloxacin compared to Lcip and Lfar. 
The most important and unique features of these dually loaded liposomes were noted when 
delivered to mature P. aeruginosa biofilms. A significant reduction of the biofilm viability was noted 
at 0.128μg/ml ciprofloxacin released by Lcip+far. However, to achieve a similar efficiency in biofilm 
viability reduction, ten-fold more ciprofloxacin was needed in the form of Lcip. These results 
strongly indicate that Lcip+far possesses an enhanced functional capability of killing established P. 
aeruginosa biofilms compared to liposomal ciprofloxacin (Lcip). It further confirms that the addition 
of farnesol to the liposomes significantly reduced the antibiotic dose needed to effectively eliminate 
biofilms. Furthermore, over 16μg/ml of free ciprofloxacin was needed to achieve a similar biofilm 
inhibition to the liposomal formulations indicating liposomal formulations offer superior anti-
biofilm properties in comparison to free ciprofloxacin. Similarly, previous studies also showed 
superior biofilm inhibitory properties when active agents were co-delivered. For instance, 
adsorption of antibiotic loaded liposomes to zinc citrate particles produced solid supported vesicles 
and provided an additional inhibitory effect against S. oralis biofilms compared to liposomal 
encapsulated antibiotics without zinc citrate particles 68.   
Co-delivery of more than one antimicrobial agent to target the site of infection via liposomes was 
hypothesized to provide a wide range of antibacterial effects with low drug toxicity as well as 
efficient drug release, even at sub-minimal concentrations For example, it was recently shown that 
co-encapsulation of bismuth with tobramycin increases the potential of P. aeruginosa killing, 
secretion of homoserine lactones, and reduces the bacterial adhesion 69. In addition, bismuth EDT-
tobramycin combination has been shown to disturb bacterial membrane integrity and biofilm 
formation 70, 71. Interestingly, co-encapsulation decreased the toxic effect of bismuth to lung 
epithelium 31, 72. In contrast, farnesol, the molecule used in our study, is known to be non-toxic for 
humans and possesses anticancer properties 73. In fact, farnesol is a common ingredient used in 
colognes and fragrances 74, thus direct contact with skin is well-tolerable. Farnesol is well-
metabolized by liver cells. Thus, the safety margin of liposomes loaded with farnesol and 
ciprofloxacin is expected to be greater compared to previously reported liposomal formulations. 
The proposed mechanisms of action of farnesol and ciprofloxacin loaded liposomes are presented 
in Figure 7. Further studies on the toxicity of these liposomal formulations need to be conducted. 
Nevertheless, a combination therapy of ciprofloxacin with farnesol in the form of liposomes, appear 
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to be a promising approach in eliminating devastating infections of P. aeruginosa such as in CF 
patients.  
Summary 
This study gives an important insight into a novel antipseudomonal biofilm strategy that 
synergistically combines microbial quorum sensing and bactericidal agents in a rationally designed 
delivery system for biofilms. The findings of this study confirmed that co-delivering farnesol and 
ciprofloxacin in liposomes allows for superior biofilm killing at significantly lower antimicrobial 
doses.  The findings of this study support further investigation into this novel drug delivery system 
in managing P. aeruginosa infections in CF models.  
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Legends 
Table 1 
The sizes, zeta potentials and polydispersity indices of various liposomal preparations 
The size of the liposomes are measured by their diameter. 
 
Figure 1 
Qualitative analyses of liposomes with fluorescent microscopy, transmission light 
microscopy and scan electron microscopy 
A. Liposomes under transmission light microscopy; note the circular and multi lamellar nature of 
liposomes. B. and C. Liposomes stained with propidium iodide under fluorescent microscopy; the 
liposomes were circular and the lipid walls of liposomes were clearly stained with fluorescent dye 
while the core appeared unstained. D. and E. Liposomes under scan electron microscopy; note the 
globular topography of liposomes. 
Figure 2 
Release of ciprofloxacin from Lcip and Lcip+far for 24h 
Total ciprofloxacin released from Lcip+far was higher than from Lcip. Both liposomes released more 
ciprofloxacin than their respective biofilm inhibitory concentrations. 
Figure 3 
Minimum biofilm inhibitory concentrations of ciprofloxacin when administered in different 
forms 
The ciprofloxacin concentration needed for an inhibition of P. aeruginosa biofilms was significantly 
lower when administered as Lcip (1.31µg/ml) and Lcip+far ((0.128µg/ml) compared to free 
ciprofloxacin (16µg/ml). Most significant effect was observed with Lcip+far (P<0.05) and the 
concentration of ciprofloxacin required in the form of Lcip+far was significantly lower than Lcip 
(P<0.05). * indicates significant differences. 
Figure 4 
Effect of liposomes on P. aeruginosa biofilms - Confocal laser scanning microscopy 
(magnification × 40) (stained using a LIVE/DEAD BacLight bacterial viability kit; Invitrogen); 
Live cells are stained in green and dead cells in red. 
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(A) P. aeruginosa 24h control biofilm; (B) P. aeruginosa biofilm treated with free ciprofloxacin 
0.128μg/ml. (C)  P. aeruginosa biofilm treated with Lcon. (D) P. aeruginosa biofilm treated with Lfar. 
(E) P. aeruginosa biofilm treated with Lcip (Final ciprofloxacin concentration was 0.128μg/ml (F) P. 
aeruginosa biofilm treated with Lcip+far (Final ciprofloxacin concentration was 0.128μg/ml.). Lcip, Lfar 
and Lcip+far, (Figure 4D, E, and F) exhibited greater degree of structural disruption, lower live: dead 
cell ratio compared to dense, spatially oriented control biofilms or biofilms treated with Lcon (Figure 
4A, and C). Lcip+far treated biofilms demonstrated the most significant disruption. Note the scanty 
biofilm architecture, and a significant proportion of dead cells compared to all other samples 
(Figure 4F). Free ciprofloxacin treated biofilm was undisrupted and appeared to be alive despite 
few isolated areas of cell death (Figure 2B) compared to Lcip and Lcip+far treated biofilms (Figure 4E 
and F) .  
Figure 5 
The depth of liposomal activity in P. aeruginosa 24h biofilms - Confocal laser scanning 
microscopy (magnification × 40) (stained using a LIVE/DEAD BacLight bacterial viability kit; 
Invitrogen); Live cells are stained in green and dead cells in red. 
(A). Lcon treated P. aeruginosa biofilm. Note the 3D biofilm architecture and the distribution of live 
and dead cells along the thickness of the biofilm (B). Lfar treated P. aeruginosa biofilm. Note the 
islands of dead bacteria and thinning of the biofilm (C). Lcip treated P. aeruginosa biofilm. Note the 
grater proportions of dead cells compared to (A) and (B) and thinning the biofilm (D). Lcip+far treated 
P. aeruginosa biofilm.  Biofilm is completely dead both superficially and throughout the thickness 
and only few live cells are visible.  
Figure 6 
Cellular level effects of liposomes on 24h P. aeruginosa biofilms – Transmission electron 
microscopy (scale 500nm) 
(A). Control P. aeruginosa 24h biofilm. Note the healthy, rod shaped, loosely packed cells with dark 
intracellular materials, intact cell membrane and slimy secretions in its immediate environment. 
Few dead cells appeared as clear cells. (B) Lcon treated 24h P. aeruginosa biofilms. Note the healthy 
heterogeneous bacteria with some dividing cells with intact cell membranes. (C) Lfar treated P. 
aeruginosa 24h biofilm. Note the similarity with (A), however, cells appear slightly larger than those 
in control biofilm. (D) Lcip treated P. aeruginosa 24h biofilms. Higher numbers of dead cells/clear 
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cells and disintegrated cell membranes were noted. Cellular contents appear leaked. Dead cells 
were surrounded by small vesicles. (E) Lcip+far treated P. aeruginosa 24h biofilms. Note the clear and 
partially ruptured cells and cellular debris throughout the microscopic field. Some disintegrated 
cells contained cytoplasm filled vesicles.  
Figure 7 
Proposed probable mechanisms and summary of P. aeruginosa biofilm disruption by 
Farnesol and ciprofloxacin loaded liposomes 
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Liposome 
type 
Diameter ±SD 
(nm) 
Zeta potential 
(mV) 
Polydispersity 
Index  
Lcip 677.8±46.6 -3.27 0.281 
Lcip+far 536.8±21.0 -0.108 0.213 
Lfar 684.0±43.8 0.086 0.391 
Lcon 2808.0±529.6 -1.66 0.086 
 
Table 1 
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